Abraham Cherrick, MD
Physical Medicine & Rehabilitation · Alexandria, VANPI 1700854577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,841 and has fallen 67.9% since, to $591 in 2025. Among physical medicine & rehabilitation clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 374 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- AbbVie$997
- Biodelivery Sciences International, Inc.$793
- Vertos Medical, Inc.$546
- Abbott$491
- Boston Scientific$413
- plus $4K from 50 others
What the payments were for
- Speaking & faculty fees$7509%
- Food & beverage$7,82091%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$750
- mild Device Kit$573
- Intracept$517
- Nexwave$144
- Qutenza$126
- INTELLIS ADAPTIVESTIM$104
How this compares
$8,591 in reported general payments places this provider in the 95th percentile of 231 physical medicine & rehabilitation providers in Virginia.
See all physical medicine & rehabilitation providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 48 | $29,743 |
| OxycontinOxycodone Hcl | 43 | $28,421 |
| BelbucaBuprenorphine Hcl | 14 | $10,550 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 351 | $8,142 |
| Morphine Sulfate ErMorphine Sulfate | 195 | $7,541 |
| Fentanyl | 53 | $4,734 |
| Chlorzoxazone | 16 | $3,936 |
| Pregabalin | 99 | $3,548 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 166 | $3,506 |
| Oxycodone Hcl | 195 | $3,270 |
| Buprenorphine | 16 | $3,016 |
| Methadone Hcl | 91 | $2,644 |
| Morphine Sulfate | 58 | $1,764 |
| Gabapentin | 102 | $1,211 |
| Hydromorphone Hcl | 63 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $1,008 | $40,29362 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $34 | $4,77974 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 physical medicine & rehabilitation providers in Virginia.
Other physical medicine & rehabilitation in Alexandria
- Peter YehAlexandria$3K
- Connie JiangAlexandria$2K
- Carlos Perez GonzalezAlexandria$1K
- Anton MatveevAlexandria$837
- Kovosh DastanWinchester$23K
- Stephanie ClopAldie$16K
- Daniel HellerWarrenton$12K
- Amanda MoranNorfolk$9K
- Mir AliRichmond$8K
- Derek BuckBluefield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.